F2RL3 Methylation in the Peripheral Blood as a Potential Marker for the Detection of Coronary Heart Disease: A Case-Control Study

Figures

• 

  FIGURE 1. The association between CHD and decreased F2RL3 methylation in the peripheral blood. The point plots show the methylation differences of CpG sites in the amplicon of F2RL3_A and F2RL3_B (A) between 184 controls and 180 CHD cases, (B) between 51 controls and 53 CHD cases, age <60 years, (C) between 133 controls and 127 CHD cases, age ≥60 years. The p-values of all the 12 measurable CpG loci in the two amplicons were calculated by logistic regression adjusted for age, gender, smoking, hypertension, TC, LDL, and batch effect. The vertical dashed line separates the two amplicons. The solid lines indicate the thresholds of p-value = 0.05.

• 

  FIGURE 2. The association between decreased F2RL3 methylation in the peripheral blood and MI cases, non-MI CHD cases, heart failure cases, and patients with minor to medium cardiac function impairment (NYHA Ⅰ&Ⅱ CHD cases). The point plots show the methylation differences of CpG sites in the amplicon of F2RL3_A and F2RL3_B (A) between 184 controls and 78 MI cases, (B) between 184 controls and 102 non-MI CHD cases, (C) between 184 controls and 145 heart failure cases, (D) between 184 controls and 124 NYHA Ⅰ&Ⅱ CHD cases. The p-values of all the 12 measurable CpG loci in the two amplicons were calculated by logistic regression adjusted for age, gender, smoking, hypertension, TC, LDL, and batch effect. The vertical dashed line separates the two amplicons. The solid lines indicate the thresholds of p-value = 0.05.

• 

  FIGURE 3. The methylation level of F2RL3 in the peripheral blood DNA as a marker for the detection of CHD in general, age ≥60 years CHD cases, MI cases, heart failure cases, and patients with minor to medium cardiac function impairment (NYHA Ⅰ&Ⅱ CHD cases). (A,C,E,G,I) ROC curve analyses for the discriminatory power of F2RL3_A_CpG_3 methylation to distinguish CHD cases, age ≥60 years CHD cases, MI cases, heart failure cases, and NYHA Ⅰ&Ⅱ CHD cases from controls. (B,D,F,H,J) The combination of F2RL3_A_CpG_3 and F2RL3_A_CpG_1 for the discrimination of CHD cases, age ≥60 years CHD cases, MI cases, heart failure cases, and NYHA Ⅰ&Ⅱ CHD cases from controls. The ROC analyses were calculated by logistic regression adjusted for age, gender, smoking, hypertension, TC, LDL, and batch effect. The gray lines represent the line of no discrimination.